CoChat

Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency

Open access
Tai, Chun-Hwei, Lee, Ni-Chung, Chien, Yin-Hsiu, Byrne, Barry J., Muramatsu, Shin-Ichi, Tseng, Sheng-Hong, Hwu, Wuh-Liang · 2022 · Molecular Therapy
Cited by 162

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Aromatic L-amino acid decarboxylase deficiency results in decreased neurotransmitter levels and severe motor dysfunction. Twenty-six patients without head control received bilateral intraputaminal infusions of a recombinant adeno-associated virus type 2 vector containing the human aromatic L-amino acid decarboxylase gene (eladocagene exuparvovec) and have completed 1-year evaluations. Rapid improvements in motor and cognitive function occurred within 12 months after gene therapy and were sustained during follow-up for >5 years. An increase in dopamine production was demonstrated by positron emission tomography and neurotransmitter analysis. Patient symptoms (mood, sweating, temperature, and oculogyric crises), patient growth, and patient caretaker quality of life improved. Although improvements were observed in all treated participants, younger age was associated with greater improvement. There were no treatment-associated brain injuries, and most adverse events were related to underlying disease. Post-surgery complications such as cerebrospinal fluid leakage were managed with standard of care. Most patients experienced mild to moderate dyskinesia that resolved in a few months. These observations suggest that eladocagene exuparvovec treatment for aromatic L-amino acid decarboxylase deficiency provides durable and meaningful benefits with a favorable safety profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2021.11.005

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 162

Metadata

Authors
Tai, C.-H., Lee, N.-C., Chien, Y.-H., Byrne, B. J., Muramatsu, S.-I., Tseng, S.-H., & Hwu, W.-L.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2022-02
Volume
30
Issue
2
Pages
509-518
ISSN
1525-0016 (ISSN-L)
OpenAlex
W3214359432
Cited by
162
References
8
FWCI
11.96
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. https://app.cochat.ai/papers/10.1016/j.ymthe.2021.11.005
The paper
Tai, C.-H., Lee, N.-C., Chien, Y.-H., Byrne, B. J., Muramatsu, S.-I., Tseng, S.-H., & Hwu, W.-L. (2022). Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2021.11.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.